Minghui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Minghui Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Cheng Ran
Department of Otolaryngology Affiliate Hospital of Hebei University Baoding China
1 shared publicationDongcheng Wang
Biomedical Barriers Research Center, Institute of Biomedical Engineering Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
1 shared publicationJia Hao
Department of Otolaryngology Affiliate Hospital of Hebei University Baoding China
1 shared publicationXiaobo Ma
Key Laboratory of Otolaryngology Head and Neck Surgery, Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Ministry of Education Capital Medical University Beijing China
1 shared publicationXin Zhang
Biomedical Barriers Research Center, Institute of Biomedical Engineering Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
1 shared publicationZhen Wang
Biomedical Barriers Research Center, Institute of Biomedical Engineering Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
1 shared publication
Latest Publications
- Open Access
- 17 October 2025
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (10) , 1813-1823
Intratympanic dexamethasone microcrystals/lidocaine‐loaded PLGA non‐spherical microparticles for local drug delivery to the inner ear
Background: Sudden sensorineural hearing loss (SSNHL), often associated with tinnitus, significantly impacts individuals' quality of life. Current treatments, such as free drugs via intravenous or intratympanic (IT) administration of dexamethasone (DEX) and lidocaine, face limitations like low bioavailability and rapid drug clearance. To address these challenges, we developed a local co‐delivery system combining DEX microcrystals (DEX MCs) and lidocaine‐loaded poly(lactic‐co‐glycolic acid) (PLGA) non‐spherical microparticles (LPNMs) for sustained drug release in the inner ear. Methods: DEX MCs and LPNMs were prepared using the traditional precipitation technique and double emulsion‐solvent evaporation, respectively. After characterizing physicochemical properties and drug release kinetics, they were dispersed in sodium hyaluronate solution for IT injection, then in vivo pharmacokinetics and biocompatibility in guinea pigs were studied. Results: DEX MCs exhibited stable dissolution, while LPNMs provided sustained lidocaine release, reducing potential side effects. In vivo studies in guinea pigs demonstrated prolonged drug retention in the perilymph and improved pharmacokinetics. Histological evaluation confirmed the good biocompatibility of this combined delivery system, with no significant inner ear damage observed. Conclusion: This co‐delivery system can be used as a depot for delivering both DEX and lidocaine to the inner ear and offers a promising approach for the synergistic treatment of SSNHL associated with tinnitus.
- 17 October 2025
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (10) , 1813-1823
Open AccessIntratympanic dexamethasone microcrystals/lidocaine‐loaded PLGA non‐spherical microparticles for local drug delivery to the inner ear
Background: Sudden sensorineural hearing loss (SSNHL), often associated with tinnitus, significantly impacts individuals' quality of life. Current treatments, such as free drugs via intravenous or intratympanic (IT) administration of dexamethasone (DEX) and lidocaine, face limitations like low bioavailability and rapid drug clearance. To address these challenges, we developed a local co‐delivery system combining DEX microcrystals (DEX MCs) and lidocaine‐loaded poly(lactic‐co‐glycolic acid) (PLGA) non‐spherical microparticles (LPNMs) for sustained drug release in the inner ear. Methods: DEX MCs and LPNMs were prepared using the traditional precipitation technique and double emulsion‐solvent evaporation, respectively. After characterizing physicochemical properties and drug release kinetics, they were dispersed in sodium hyaluronate solution for IT injection, then in vivo pharmacokinetics and biocompatibility in guinea pigs were studied. Results: DEX MCs exhibited stable dissolution, while LPNMs provided sustained lidocaine release, reducing potential side effects. In vivo studies in guinea pigs demonstrated prolonged drug retention in the perilymph and improved pharmacokinetics. Histological evaluation confirmed the good biocompatibility of this combined delivery system, with no significant inner ear damage observed. Conclusion: This co‐delivery system can be used as a depot for delivering both DEX and lidocaine to the inner ear and offers a promising approach for the synergistic treatment of SSNHL associated with tinnitus.